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M A J O R A R T I C L E
Pan-Viral Screening of Respiratory Tract Infections
in Adults With and Without Asthma Reveals
Unexpected Human Coronavirus and Human
Rhinovirus Diversity
Amy Kistler,1 Pedro C. Avila,4 Silvi Rouskin,1 David Wang,5 Theresa Ward,2 Shigeo Yagi,3 David Schnurr,3
Don Ganem,1 Joseph L. DeRisi,1 and Homer A. Boushey2
1Howard Hughes Medical Institute, Departments of Medicine, Biochemistry, and Microbiology, and 2Department of Medicine, University
of California, San Francisco, and 3Viral and Rickettsial Disease Laboratory, California Department of Health Services, Richmond; 4Division
of Allergy-Immunology, Northwestern University Feinberg School of Medicine, Chicago, Illinois; 5Departments of Molecular Microbiology
and of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri
(See the editorial commentary by Gern and Busse, on pages 810–1.)
Background. Between 50% and 80% of asthma exacerbations are associated with viral respiratory tract infec-
tions (RTIs), yet the influence of viral pathogen diversity on asthma outcomes is poorly understood because of
the limited scope and throughput of conventional viral detection methods.
Methods. We investigated the capability of the Virochip, a DNA microarray–based viral detection platform,
to characterize viral diversity in RTIs in adults with and without asthma.
Results. The Virochip detected viruses in a higher proportion of samples (65%) than did culture isolation
(17%) while exhibiting high concordance (98%) with and comparable sensitivity (97%) and specificity (98%) to
pathogen-specific polymerase chain reaction. A similar spectrum of viruses was identified in the RTIs of each
patient subgroup; however, unexpected diversity among human coronaviruses (HCoVs) and human rhinoviruses
(HRVs) was revealed. All but one of the HCoVs corresponded to the newly recognized HCoV-NL63 and HCoV-
HKU1 viruses, and 120 different serotypes of HRVs were detected, including a set of 5 divergent isolates that
formed a distinct genetic subgroup.
Conclusions. The Virochip can detect both known and novel variants of viral pathogens present in RTIs. Given
the diversity detected here, larger-scale studies will be necessary to determine whether particular substrains of
viruses confer an elevated risk of asthma exacerbation.
Between 50% and 80% of asthma exacerbations are
associated with viral respiratory tract infections (RTIs)
[1, 2]. In young children, a variety of viral pathogens
accompany wheezing episodes, most notably respira-
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tory syncytial virus (RSV) (reviewed in [3]). In older
children [2] and adults [4, 5], human rhinoviruses
(HRVs) are implicated in the majority of cases, with
variable contributions from human coronaviruses
(HCoVs), influenza viruses, parainfluenza viruses, RSV,
and human metapneumovirus (HMPV) (reviewed in
[6]). However, the factors that determine the clinical
outcomes associated with RTIs in persons with asthma
are not well understood. Host factors governing in-
flammatory and immune responses have been dem-
onstrated to influence whether a host with asthma ex-
periencing a viral RTI will develop an exacerbation of
symptoms [7–10]. In contrast, it remains unresolved
whether variation in viral pathogens may also influence
this outcome. For example, despite the prominent as-
sociation between HRVs and asthma exacerbation, de-
liberate inoculation of a laboratory-adapted HRV-16
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isolate into subjects with asthma did not produce wheezing,
despite efficient infection and the generation of upper respi-
ratory tract symptoms [11–16]. Although these experimental
HRV inoculation studies have not demonstrated clinically sig-
nificant exacerbations, a small decline in pulmonary function
has been observed [17, 18]. Likewise, not every cold in subjects
with asthma is associated with exacerbation of asthma symp-
toms. These findings raise the possibility that some respiratory
viral pathogens may have greater potential than others of trig-
gering asthma exacerbations in susceptible hosts.
If this is so, then the spectrum of viral isolates recovered
from RTIs in persons with asthma who experience exacerba-
tions should differ from that in persons with asthma whose
RTIs do not trigger exacerbations. Few prior studies have at-
tempted to make this comparison, and those that did have
generally not used methods that can differentiate among the
different subtypes of viruses within a family. Estimating the
number of HRV isolates, rather than identifying them by se-
rotype or genotype, may be insufficient given that certain iso-
lates of HRV are demonstrably inefficient at triggering asthma
on inoculation.
Part of the reason for the paucity of prior studies of this
type derives from the limitations of conventional viral detection
methods. Viral culture is insensitive, and antigen testing, while
reasonably sensitive, is (1) unavailable for several important
classes of pathogen, notably HRVs and HCoVs, and (2) not
designed to discriminate among isolates of a given viral species.
Polymerase chain reaction (PCR) methods have high sensitivity
but are limited to the detection of previously characterized or
highly conserved viral sequences.
We have developed an alternative, comprehensive strategy
for viral detection that uses the Virochip, a DNA microarray
bearing the most conserved sequences of all known viruses of
humans, animals, plants, and microbes [19, 20]. In addition
to the ability of the Virochip to detect known viruses, it can
also detect new members of known virus families by cross-
hybridization—a significant advantage over PCR-based meth-
ods [20–23]. Here, we have applied the Virochip to an ongoing
prospective study designed to analyze the diversity of viruses
that cause RTIs in adults with and without asthma, with par-
ticular attention given to those that provoke asthma attacks.
SUBJECTS, MATERIALS, AND METHODS
Subject recruitment. We recruited adults with and without
asthma by advertising on a community Web site (craigslist;
http://sfbay.craigslist.org/), by posting flyers on campus, and
by sending e-mail messages to subjects who had responded to
previous advertisements for research studies. Participant re-
cruitment started in the fall of 2001 and extended through the
end of December 2004. The announcements requested that
subjects contact us within 48 h of the onset of “cold” symptoms.
We evaluated subjects first within 1–3 days of cold onset (visit
1), then again between days 4 and 7 of cold symptoms (visit
2), and at 6 weeks or longer thereafter to assess baseline status
(visit 3). Eighty-three subjects were enrolled; 53 had asthma,
and 30 did not. Asthma was defined as a history of asthma
symptoms (recurrent dyspnea, wheezing, and chest tightness)
associated with a positive methacholine test result [8]. Subjects
without asthma had neither a history of asthma symptoms nor
a positive methacholine test result. All were informed of the
purposes, procedures, and risks of participating, and all signed
informed-consent forms approved by the University of Cali-
fornia, San Francisco, Committee of Human Research.
Study procedures. At the first visit, participants completed
questionnaires on demographics, medical history, asthma his-
tory, and date of onset of cold symptoms. At each visit, par-
ticipants provided information on the severity of current upper
and lower respiratory tract symptoms by use of a validated cold
questionnaire [24] and diary form [8] that have been described
elsewhere. Spirometry measurements (forced expired volume
in 1 s [FEV1] and forced vital capacity [FVC]) were obtained,
and the percentage predicted was calculated using Crapo equa-
tions. Nasal lavage (NL) was then performed by instilling 5 mL
of warmed normal saline into each nostril and, after a 20-s
dwell time, having the subject expel the nasal contents into a
plastic cup. Subjects with asthma recorded symptom severity
and a.m. and p.m. peak flow measurements (AirWatch; iMetri-
kus) in a diary twice daily for 7 days after visit 1 and 7 days
before visit 3. The visit procedures were repeated at day 5–7
and at baseline (6 weeks or longer) after the onset of cold
symptoms.
Definition of asthma exacerbation. Before initiating the
study, we defined asthma exacerbation as either a worsening
of asthma symptoms that required corticosteroids (systemic or
topical) or a worsening of symptoms on the basis of study
measurements. The latter was defined by an increase in daily
asthma symptom score of 10 points or more (range, 0–50
points) above the baseline daily average for at least 2 days
together with at least 1 of the following: (1) decrease in FEV1
by 10% or more at any of the first 2 visits; (2) decrease in peak
flow measurements by 20% or more for at least 2 days during
the cold week; or (3) increase in daily albuterol use of 4 puffs
or more for at least 2 days during the cold week.
Specimen processing. NL specimens from visit 1 (days 1–
3 after the onset of cold symptoms) were analyzed for the
presence of virus by PCR, viral culture, and Virochip microarray
analysis. For microarray analysis and PCR, 1 mL of homoge-
nized NL specimen was mixed with 3.5 mL of RLT buffer
(Qiagen) containing 2-mercaptoethanol and then frozen at bed-
side in dry ice and stored at 80C.
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Figure 1. Summary of study participant distribution and Virochip results. Asterisks indicate viruses detected in specimens containing double infections.
HRV‘X’ is a divergent human rhinovirus (HRV) subgroup identified by array and sequence analysis. HCoV, human coronavirus; HMPV, human meta-
pneumovirus; HPIV, human parainfluenza virus; IF, influenza virus; RSV, respiratory syncytial virus.
Viral culture isolation. A 0.1-mL NL aliquot was cultured
in duplicate with a combination of 5 different cell lines (HeLa,
WI38, MRC5, primary monkey kidney, and HFDL, an in-house
line of human fetal diploid lung cells [California Department
of Health Services Viral and Rickettsial Disease Laboratory,
Richmond]). Some specimens were inoculated into all 5 cell
types, and all were cultured in at least 3, including primary
monkey kidney and human fetal diploid. If cytopathic effect
occurred, viral antigen detection tests (Respiratory Viral An-
tigen Detection Kit; Chemicon) were performed to identify
antigens from adenovirus, RSV, influenza viruses A and B, and
parainfluenza viruses 1, 2, and 3. Enteroviruses and rhinovi-
ruses were differentiated by reactivity with the monoclonal pan-
enterovirus reagent from Chemicon and the enterovirus mono-
clonal antibody from Dako Cytomation (enterovirus clone
5-D8/1).
RNA extraction. Samples were masked and total RNA was
extracted with an on-column recombinant DNase treatment
step using the RNeasy Miniprep Kit (Qiagen), in accordance
with the manufacturer’s instructions.
Amplification and microarray analysis. RNA was ran-
domly amplified and labeled and was then hybridized to the
Virochip microarray as described elsewhere (protocol S1 in
Wang et al. [19]). Microarrays were scanned using the Axon
4000B scanner and GenePix software (version 3; Axon Instru-
ments). A.K., who was blinded to the viral culture isolation
and HRV PCR results, interpreted the hybridization signatures.
Epredict, a computational tool developed for the Virochip array
hybridization signature, was used to determine the Virochip
results, with the P value cutoff for positivity set at .05, as de-
scribed elsewhere [25]. Samples for which multiple viruses met
this threshold were further evaluated by hierarchical cluster
analysis of sum-normalized background-subtracted array hy-
bridization intensities from all NL specimens, by use of Cluster
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Figure 2. Clustogram of Virochip hybridization signatures. A, Nasal lavage specimens (X-axis) clustered according to the sum-normalized fluorescent
intensity of array signal, with major viral oligonucleotide clusters (Y-axis) identified at right. B, Zoomed-in view of the 3 human coronavirus (HCoV)
signatures detected by the Virochip. Each hybridization signature is boxed in white, with its corresponding HCoV type (OC43, NL63, and HKU1) indicated
at the top of the clustogram; the identity of oligos lighting up within the clusters are indicated at right. HPIV, human parainfluenza virus; IF, influenza
virus; RSV, respiratory syncytial virus.
software (version 3) [26]. Co-occurrence of samples within
clusters was used to make calls for specimens that either had
multiple significant Epredict scores or had no significant Epre-
dict scores. All viral-positive calls were confirmed by recovery
of viral sequence.
Specific PCR for HRV detection. For each sample, 3 mL of
the randomly amplified material was used for independent PCR
to detect and sequence the HRV VP4/VP2 capsid gene junction,
as described elsewhere [27]. The VP4/VP2 PCRs were performed
in a blinded manner. Primers 9656-reverse (5′-GCATCIGGYAR-
YTTCCACCACCANCC-3′; positions 1083–1058 of HRV-1b; Na-
tional Center for Biotechnology Information [NCBI] accession
number D00239) and 9895-forward (5′-GGGACCAACTACTT-
TGGGTGTCCGTGT-3′; positions 534–560 of HRV-1b) were
used for PCR (35 cycles of 94C for 30 s, 58C for 30 s, and
72C for 30 s).
Comparative sequence analysis of recovered HRV VP4/VP2
PCR products. ClustalW (version 1.82) was used to align the
VP4/VP2 capsid gene junction sequences obtained for the clin-
ical isolates of HRV for all 102 reference HRV serotypes [27].
Neighbor-joining phylogenetic trees were generated from the
resulting alignment using the PHYLIP package (version 3.2) [28].
Specific PCR for HCoVs. For each of the 8 HCoV-positive
samples identified by Virochip microarray analysis, 3 mL of the
randomly amplified material was used for PCR to detect a 440-
bp region of the polymerase gene using pan-CoV primers (5′-
GGTTGGGACTATCCTAAGTGTGA-3′ and 5′-CCATCATCA-
GATAGAATCATCATA-3′) that have been described elsewhere
[29]; amplification was with 40 cycles of 94C for 60 s, 48C
for 60 s, and 72C for 60 s.
Sequence analysis of HCoV PCR products amplified from
clinical isolates. PCR products were extracted using QIA-
quick (Qiagen) and were either sequenced directly using path-
ogen-specific primers or subcloned into pCR2.1 TOPO vector
(Invitrogen) and sequenced using M13 forward and M13 re-
verse primers with the BigDye Cycle Sequence Kit on an ABI
3130 automated sequencer (Applied Biosystems). The identity
of each of the HCoVs in the present study was inferred on the
basis of the highest scoring match from BLAST analysis (version
2.2.13) [30] of the resulting sequences.
Genome sequence recovery from HRV‘X’-1 and HRV‘X’-2.
Amplified cDNA was subcloned into pCR2.1 TOPO plasmid
(Invitrogen). Three hundred eighty-four colonies were picked,
and DNA was purified by magnetic bead isolation followed by
DNA sequencing using the BigDye Cycle Sequence Kit/ABI
3730xl sequencer. Sequence reads were assembled by use of
CONSED for Linux (version 13.4) [31]. Assemblies were
screened by BLAST analysis [30] to remove any contigs with
human or bacterial sequence similarity. Gaps in assemblies were
filled by synthesis of oligonucleotides with at least 100 bp of
overlapping sequence with available contigs.
Accession numbers. GenBank accession numbers for the
sequenced viruses presented here are EF077237-EF077281. The
GEO database (http://www.ncbi.nlm.nih.gov/geo/) series ac-
cession number for all Virochip microarray data presented here
is GSE8053.
RESULTS
Performance of the Virochip relative to conventional viral
detection methods. The first goal of our analysis was to assess
the performance of the Virochip relative to conventional viral
detection methods. To do this, we used a set of NL specimens
from an ongoing prospective study of naturally acquired upper
RTIs (NatURIs) in adults with and without asthma. A total of
82 cold events captured from this study were available for anal-
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Table 1. Detection rates for and viruses detected by culture and
the Virochip microarray.
Viral detection Culture Virochip
Samples viral positive, total no. 14 53
Samples viral negative, total no. 68 28
Samples tested, total no. 82 82
Overall detection rate, % 17 65
Human rhinovirus 14 37
Human coronavirus 0 8a
Respiratory syncytial virus 1b 5b,c
Influenza virus 2a 3a
Human parainfluenza virus 0 2
Human metapneumovirus 0 1
Multiple viruses 1 2
a Respiratory syncytial virus also detected in 1 specimen.
b Influenza virus also detected in 1 specimen.
c Human coronavirus also detected in 1 specimen.
Table 2. Agreement between polymerase chain re-
action (PCR) and the Virochip microarray for detec-
tion of rhinovirus.
Result
PCR
positive
PCR
negative Total
Virochip positive 36 1 37
Virochip negative 1 43 44
Total 37 44 81
ysis. Breakdown of participants, specimens, associated clinical
outcomes, and corresponding Virochip results are summarized
in figure 1. Each NatURI specimen was analyzed independently
in a blinded manner by 3 distinct viral detection methods:
Virochip analysis and culture isolation for 9 common respi-
ratory pathogens (HRV; RSV; influenza viruses A and B; human
parainfluenza viruses 1, 2, and 3; adenovirus; and human en-
terovirus) and PCR for HRV. Where the Virochip detected
viruses, follow-up PCR and sequence recovery was performed
to confirm the presence of the detected viral species.
A high proportion of specimens tested positive for virus by
Virochip analysis (65%). Reflective of the outpatient setting of
our study, the 2 most prevalent virus families detected by the
Virochip corresponded to HRVs and HCoVs (figure 2A and
table 1). Four additional viruses generally thought to be as-
sociated with lower RTIs—RSV and the closely related HMPV,
influenza virus, and human parainfluenza virus—were also de-
tected. We also detected double infections (RSV plus HCoV
and RSV plus influenza virus) (figure 2A and table 1).
In contrast, virus was detected by culture isolation in only
17% of samples. Three different viral pathogens (HRV, RSV,
and influenza virus) and 1 double infection were detected by
this method (table 1). Head-to-head comparison of these 2
assays yielded an overall low concordance (55%). Virtually all
of the discordant results (34/35) corresponded to results that
were positive by the Virochip but negative by culture isolation.
These results were not surprising, given the known limita-
tions of viral culture isolation [32]. We also compared the
performance of the Virochip to pathogen-specific PCR, which
is known for its high sensitivity. To address this in a statistically
significant manner, we focused on PCR detection of HRV [27],
the most common pathogen detected in the study population.
We found excellent concordance (98% agreement) between Vi-
rochip and HRV-specific PCR results, indicating that Virochip
analysis is a highly sensitive (97%) and specific (98%) viral
detection method in comparison to pathogen-specific PCR (ta-
ble 2).
Detection of both known and novel HCoVs by the Virochip.
Analysis of Virochip hybridization signatures for the 8 HCoVs
detected among the study subjects revealed 3 distinct signatures
(figure 2B). PCR recovery and sequence analysis of a fragment
of the HCoV polymerase gene [29] revealed that each of these
signatures corresponded to a distinct HCoV subtype: (1)
HCoV-OC43, (2) HCoV-NL63, and (3) HCoV-HKU1. Each of
these isolates shared between 97% and 100% sequence identity
with the corresponding HCoV polymerase gene sequences pres-
ent in the NCBI database.
Surprisingly, the bulk of the HCoVs detected in this out-
patient population did not correspond to the more common
HCoV types (OC43 and 229E) historically detected in US adult
RTIs [33]. Of the 8 HCoVs detected in this study population,
4 were HCoV-NL63, 3 were HCoV-HKU1, and only 1 was
HCoV-OC43. The different HCoV types were detected in sam-
ples collected at different times during the study. All 4 of the
HCoV-NL63 isolates were detected in persons with colds that
occurred during the early winter of 2002, whereas the HCoV-
HKU1 isolates were detected during the late fall of 2001 (1
isolate) and the early winter of 2004 (2 isolates). The sole
HCoV-OC43 isolate was identified during the mid-fall of 2004.
No HCoVs infections were detected in this study population
in 2003. Interestingly, HCoV-NL63 was detected only in persons
with asthma, and 3 of the 4 infections were accompanied by
an exacerbation of asthma symptoms.
Detection of a divergent subgroup of HRVs by the Virochip.
The most commonly detected virus in our study population
was HRV (figures 1 and 2A and table 1). To investigate HRV
diversity, we sequenced the junction of the VP4/VP2 capsid
genes of the HRV isolates and performed phylogenetic analysis
of these sequences and of the published sequences from all 102
HRV serotype reference strains [27]. We found that the Viro-
chip hybridization signatures we observed corresponded to ∼29
different HRVs: 16 HRVA serotypes, 8 HRVB serotypes, and a
novel third set of 5 divergent HRVs (referred to as HRV‘X’;
figure 3), which possessed slightly more sequence similarity to
HRVA than to HRVB reference serotypes.
None of the divergent HRV‘X’ isolates were culturable; thus,
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Figure 3. Phylogenetic grouping of human rhinovirus (HRV) VP4/VP2 sequences. Red indicates HRVA subgroup members, blue indicates HRVB
subgroup members, green indicates an HRV87 rhino/entero outlier, and the dashed circle highlights a branch of divergent HRV isolates (HRV‘X’). The
nos. at the ends of the branches indicate HRV reference serotype identifiers, and the circles at the ends of branches indicate the participant type
and clinical outcome accompanying the cold event for clinical isolates.
unambiguous detection and classification of these isolates by
conventional serotyping [34], drug susceptibility [35], or re-
ceptor-type usage assays [36] was not possible. Recovery of
complete coding sequence from 2 of the HRV‘X’ isolates
(HRV‘X’-1 and HRV‘X’-2) and analysis of their sequence iden-
tity with a representative subset of 27 fully sequenced HRVA
subgroup genomes and 7 fully sequenced HRVB subgroup ge-
nomes [37] indicated that these HRV‘X’ isolates were indeed
HRVs.
Scanning pairwise identity revealed that the differences be-
tween the HRV‘X’ and the HRVA subgroup genomes were not
confined to a single locus but spanned the entire genome (figure
4). Although the VP4/VP2 phylogenetic analysis indicated that
the HRV‘X’ isolates were more similar to HRVA than HRVB
reference serotype strains, comparison of the level of genome-
wide sequence identity shared within the fully sequenced subset
of HRVA genomes to the levels of sequence identity shared
between the HRVA and the HRV‘X’ isolates showed that the
HRV‘X’ isolates were almost as genetically distinct from HRVA
as the HRVB subgroup genomes (figure 4). Moreover, pairwise
sequence identity between the HRV‘X’ genomes was much
lower than that detected among the fully sequenced HRVA or
HRVB subgroup genomes (data not shown). Taken together,
these data demonstrate that these HRV‘X’ isolates correspond
to a novel divergent subgroup of HRV and suggest that this
divergent branch of HRV‘X’ isolates may possess a higher level
of genetic diversity than seen previously in the HRVA and
HRVB subgroups.
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Figure 4. Comparison of genomewide pairwise nucleotide sequence identity of human rhinovirus (HRV) A, HRVB, and HRV‘X’ genomes. Top, HRV
genome organization. Black bars above the genome schematic indicate classes of gene products and gene product identities, where known (ATPase,
DEXH-box ATPase protein; NCR, noncoding region; POL, RNA-dependent RNA polymerase; PRO, viral protease; VP, viral protein; VPg, viral protein
genomic encoding the 5′ protein that caps the viral genome). Gray shading of every other gene in the genome is provided for orientation in the lower
panels. Coordinates for gene boundaries derived from alignment of 34 HRV reference genomes are shown below the genome schematic. The average
percentage pairwise nucleotide identity scans were performed using a window of 100 nt, advanced in single-nucleotide steps across the genome.
The red plot shows a representative subset of HRVA genome sequences ( ), the black plots show fully sequenced HRV‘X’ genomes comparednp 27
with HRVA genomes, and the blue plot shows fully sequenced HRVB ( ) and HRVA ( ) genomes. Dashed lines and the percentages shownnp 7 np 27
at right indicate the overall genomewide average pairwise nucleotide identity for each comparison shown.
DISCUSSION
This is the first prospective study to use a pan-viral detection
strategy to investigate the influence of viral pathogens on clin-
ical outcome in RTIs in persons with asthma. We find that,
like PCR, the Virochip technology is superior to standard cul-
ture isolation methods for detection of viral pathogens. More-
over, the Virochip exhibits comparable sensitivity and specific-
ity to pathogen-specific PCR. On the whole, the distribution
and proportion of distinct viral pathogens detected by the Vi-
rochip agrees with previous PCR-based analyses of viral path-
ogens associated with upper RTIs and those accompanied by
exacerbation of asthma symptoms [3, 38]. However, Virochip
analysis has allowed us to uncover a remarkable amount of
diversity among the viral pathogens in this relatively small study
population. This diversity indicates that future studies that seek
to link a particular virus or set of viruses to a discrete clinical
outcome, such as exacerbation of asthma symptoms, will need
to include large numbers of subjects and use pan-viral detection
methods (such as the Virochip) that can differentiate among
such isolates.
Two observations of viral diversity uncovered by Virochip
analysis of NL specimens derived from this study are partic-
ularly noteworthy. First, the diversity and distribution of
HCoVs detected in the present study were surprising. The 2
more recently described HCoV-HKU1 and HCoV-NL63 were
the predominant HCoVs rather than HCoV-OC43 and HCoV-
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229E, which have been traditionally implicated in up to 15%
of common colds in the US adult population [32]. Here, instead
we see HCoV-NL63 and HCoV-HKU1 making up approxi-
mately that same proportion of colds detected in our study
population. Given that HCoV-NL63 and HCoV-HKU1 have
not been implicated previously as significant players in out-
patient respiratory tract illnesses among immunocompetent
adults in the United States [39, 40], these results were unex-
pected. No HCoV-229E isolates and only a single HCoV-OC43
isolate were detected in this study group, despite the fact that
independent studies with the Virochip have demonstrated that,
when present, both HCoV-OC43 and HCoV-229E are readily
detectable (C. Y. Chiu, A. Urisman, T. L. Greenhow, submitted).
Further analysis will be required to determine whether the pat-
terns of HCoVs detected here reflect an increased susceptibility
of adults with asthma to contract these HCoVs, the arrival of
a local outbreak of these HCoV types, or an actual shift in the
prevalence of the distinct HCoVs circulating in the US adult
population.
Second, the Virochip detected remarkable and unanticipated
diversity among HRV isolates. In addition to detecting almost
30 distinct HRV species closely related to known reference HRV
serotypes, we also identified a subgroup of genetically distinct
HRVs in a significant fraction (5/37) of the clinical isolates of
HRV. Although the clinical significance of HRV diversity re-
mains incompletely understood, the detection of such a high
level of genetic divergence among HRV strains captured in this
relatively small study population indicates that the standard
HRV reference serotypes (which were characterized almost 30
years ago) do not adequately describe the diversity of currently
circulating HRVs.
We do not believe that these HRV‘X’ strains are an anom-
alous subgroup of HRVs unique to this study population be-
cause (1) a similar proportion of divergent HRV strains were
detected by Virochip analysis in an unrelated cohort of pediatric
subjects with RTIs (C. Y. Chiu, A. Urisman, T. L. Greenhow,
submitted); (2) divergent HRVs have also been recently iden-
tified in a study of pediatric respiratory infections in Australia
[41]; (3) based on the 5′ noncoding region sequence alone, vir-
tually identical isolates of HRV have been reported in indepen-
dent analyses of HRV infections among Europeans [42]; and (4)
recent independent application of a distinct pan-viral detection
tool, MassTag PCR analysis, has also documented a set of highly
diverged HRVs circulating in the US population [43].
Comparison of the VP4 sequences of the HRV‘X’ strains
identified here suggests that one of the HRV‘X’ strains (HRV‘X’-
2) possesses high sequence similarity (98% identity with VP4
sequence DQ875926) to one of the divergent HRVs recently
reported by Lamson et al. [43]. However, the VP4 sequences
in the other 4 HRV‘X’ strains identified here possess !85%
nucleotide sequence identity with the set of divergent HRVs
identified by Lamson et al. [43]. The identification of 2 distinct
sets of genetically divergent HRV clinical isolates indicates that
the set of previously unrecognized HRVs currently circulating
in the United States may be quite large. A deeper knowledge
of the extent of the current HRV diversity should inform future
studies of the role played by HRV strains in asthma exacer-
bations, given that a high proportion of such events are at-
tributable to infection by these agents.
In sum, the present data demonstrate that the Virochip cap-
tures the entire spectrum of known respiratory viral pathogens
in a single test, exhibits excellent sensitivity, and provides the
capacity to identify as-yet-undiscovered agents. The application
of the Virochip to prospective clinical studies should enable us
to develop a comprehensive picture of the diversity of viral
pathogens present during infection, a critical missing piece of
the puzzle required to advance our understanding of how dif-
ferent viral pathogens influence the course and spectrum of
disease.
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